Who We Are
- We are Orexo’s US operation, and we are integral to bringing innovative treatment solutions to patients in the United States.
- Our organization is focused on commercializing ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII) in the US market.
- We also offer digital mental health programs designed to help patients with Opioid Use Disorder (OUD), alcohol management, and depression.
- We have a strong, experienced US Leadership Team.
Who We Serve
- Patients with opioid dependence or OUD
- Patients with addiction, alcohol abuse, or depression
- Patients with mental illnesses looking to increase their access to healthcare
What We Offer
Through healthcare professionals, we offer:
- ZUBSOLV (buprenorphine and naloxone) sublingual tablets (CIII). Please see full Prescribing Information here.
We also offer the following digital mental health programs developed in collaboration with GAIA (MODIA®) and solely by GAIA (Vorvida® and Deprexis®):
- MODIA is designed to help patients with OUD develop behavioral coping skills and provide educational information, reminders, and motivational guidance.
- Vorvida is designed for individuals who want to reduce their alcohol use and manage their drinking behavior.
- Deprexis is designed for patients with depression to help them create more positive thoughts and behaviors using trusted Cognitive Behavioral Therapy (CBT)-based techniques.
Orexo Digital Health Disclaimers
MODIA is not a healthcare provider and does not provide medical advice, diagnosis, or specific treatment, and is marketed under FDA enforcement discretion.
Vorvida is marketed as a general wellness product. Vorvida is not a healthcare provider and does not provide medical advice, diagnosis, or treatment.
Deprexis is not a healthcare provider and does not provide medical advice, diagnosis, or standalone treatment, and is marketed under FDA enforcement discretion.
Orexo US, Inc. Corporate Governance
For compliance issues or concerns, please submit a report via the link below or call +1 (844) 251-4251.